PE20070945A1 - Una formulacion farmaceutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubilizante de dicha composicion solida de taxano, y un conjunto de elementos (kit - Google Patents

Una formulacion farmaceutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubilizante de dicha composicion solida de taxano, y un conjunto de elementos (kit

Info

Publication number
PE20070945A1
PE20070945A1 PE2007000062A PE2007000062A PE20070945A1 PE 20070945 A1 PE20070945 A1 PE 20070945A1 PE 2007000062 A PE2007000062 A PE 2007000062A PE 2007000062 A PE2007000062 A PE 2007000062A PE 20070945 A1 PE20070945 A1 PE 20070945A1
Authority
PE
Peru
Prior art keywords
taxane
composition
solid composition
lyofilized
pharmaceutical formulation
Prior art date
Application number
PE2007000062A
Other languages
English (en)
Spanish (es)
Inventor
Jose Lucio Nunez
Jose Bernardo Itusparre
De Itusparre Nora Adriana Moyano
Antonio Osvaldo Bouzada
Original Assignee
Eriochem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070945(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eriochem Sa filed Critical Eriochem Sa
Publication of PE20070945A1 publication Critical patent/PE20070945A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
PE2007000062A 2006-01-20 2007-01-19 Una formulacion farmaceutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubilizante de dicha composicion solida de taxano, y un conjunto de elementos (kit PE20070945A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AR20060100208A AR054215A1 (es) 2006-01-20 2006-01-20 Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit

Publications (1)

Publication Number Publication Date
PE20070945A1 true PE20070945A1 (es) 2007-10-07

Family

ID=38134453

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007000062A PE20070945A1 (es) 2006-01-20 2007-01-19 Una formulacion farmaceutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubilizante de dicha composicion solida de taxano, y un conjunto de elementos (kit
PE2007000063A PE20071243A1 (es) 2006-01-20 2007-01-19 Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) para la preparacion de una formulacion inyectable de taxano

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2007000063A PE20071243A1 (es) 2006-01-20 2007-01-19 Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) para la preparacion de una formulacion inyectable de taxano

Country Status (15)

Country Link
US (2) US20090215883A1 (enExample)
EP (2) EP1994925A4 (enExample)
JP (2) JP2009523770A (enExample)
AR (1) AR054215A1 (enExample)
AU (1) AU2007206877A1 (enExample)
BR (2) BRPI0706931A2 (enExample)
CA (2) CA2637893A1 (enExample)
GT (2) GT200800145A (enExample)
MX (2) MX2008009358A (enExample)
NZ (2) NZ569783A (enExample)
PE (2) PE20070945A1 (enExample)
RU (1) RU2429837C2 (enExample)
UY (2) UY30099A1 (enExample)
WO (2) WO2007082978A1 (enExample)
ZA (2) ZA200805704B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003299795A1 (en) * 2002-12-20 2004-07-22 Xeris Pharmaceuticals, Inc. Intracutaneous injection
DK1583562T3 (da) * 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, beslægtede forbindelser og anvendelser deraf
BRPI0520032A2 (pt) 2005-02-18 2009-04-14 Angiochem Inc moléculas para transportar um composto através da barreira hematoencefálica
DK2233156T3 (da) 2005-07-15 2013-08-05 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
CA2683712A1 (en) * 2007-04-20 2009-01-15 Sun Pharmaceutical Industries Limited Pharmaceutical compositions
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
AU2008269179A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without Tween 80
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
AR063111A1 (es) * 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
KR101478779B1 (ko) 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
AU2009238187B2 (en) * 2008-04-18 2014-03-06 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CA2740317A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
BRPI0922611A2 (pt) 2008-12-17 2018-11-06 Angiochem Inc inibidores de metaloproteína de matriz de membrana tipo 1 e usos dos mesmos
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
EP2448965A4 (en) 2009-07-02 2015-02-11 Angiochem Inc MULTIMEPEPTID CONJUGATES AND ITS USES
WO2011025838A1 (en) * 2009-08-25 2011-03-03 Abraxis Bioscience, Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
PL2493466T3 (pl) 2009-10-29 2021-11-15 Sanofi Mature Ip Nowe przeciwguzowe zastosowanie kabazytakselu
EP2521539A4 (en) * 2009-12-31 2014-11-26 Mannkind Corp INJECTABLE PREPARATIONS FOR PARENTERAL ADMINISTRATION
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前-乳劑調配物及其製造與使用之方法
MX341082B (es) 2010-05-03 2016-08-08 Teikoku Pharma Usa Inc Formulaciones de pro-emulsion de taxano no acuosas y metodos para hacer y usar las mismas.
AR077384A1 (es) * 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
KR101978527B1 (ko) 2011-03-10 2019-09-03 엑스에리스 파머수티클스, 인크. 펩티드 약물의 비경구 주입을 위한 안정한 제형
CA2853942C (en) 2011-10-31 2020-08-25 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
EP2958554B1 (en) * 2013-02-19 2018-06-06 Synthon BV Stable compositions of bendamustine
EP3871709A1 (en) 2014-08-06 2021-09-01 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
EP2985038A1 (en) * 2014-08-12 2016-02-17 Azad Pharma AG Lyophilized API preparation
US20170360791A1 (en) * 2014-12-04 2017-12-21 Astex Pharmaceuticals, Inc. Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs
US9763892B2 (en) 2015-06-01 2017-09-19 Autotelic Llc Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods
CA3026452C (en) * 2015-06-04 2023-03-21 Crititech, Inc. Nozzle assembly and methods for use
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
TWI752750B (zh) 2015-09-30 2022-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
SG11201808125RA (en) 2016-04-04 2018-10-30 Crititech Inc Methods for solid tumor treatment
RU2708329C2 (ru) * 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
EP4378463A3 (en) 2017-06-02 2024-10-23 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
CN111465389B (zh) * 2017-09-07 2022-06-21 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法
KR20200064112A (ko) 2017-10-03 2020-06-05 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
CN107496352A (zh) * 2017-10-13 2017-12-22 深圳万乐药业有限公司 一种多烯紫杉醇药物组合物及其制备方法
US12414914B2 (en) * 2018-07-25 2025-09-16 Bika Biotechnology (Guangzhou) Co., Ltd Docetaxel composition for injection and preparation method therefor
KR20220002860A (ko) 2018-12-21 2022-01-07 모드라 파마슈티컬스 비.브이. 피크 혈장 수준의 제어에 의한 도세탁셀을 사용하는 암 치료

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
HUP9701945A3 (en) 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
US5922754A (en) 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
IL146659A0 (en) * 1999-05-27 2002-07-25 Acusphere Inc Porous drug matrices and method of manufacture thereof
WO2000075281A2 (en) 1999-06-09 2000-12-14 University Technology Corporation Supercritical fluid-assisted nebulization and bubble drying
US20010047162A1 (en) * 2000-02-17 2001-11-29 Yasumi Yugari Injection kit and injection device
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
ES2390066T3 (es) * 2000-05-12 2012-11-06 Samyang Biopharmaceuticals Corporation Procedimiento para la preparación de micelas poliméricas mediante separación de fase de un copolímero en bloque
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
PL203300B1 (pl) * 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
US6919370B2 (en) 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US20040256749A1 (en) 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20030099674A1 (en) * 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
KR100573289B1 (ko) 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
KR100508518B1 (ko) 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
US6759539B1 (en) * 2003-02-27 2004-07-06 Chaichem Pharmaceuticals International Process for isolation and purification of paclitaxel from natural sources
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN1850056A (zh) * 2006-03-06 2006-10-25 杨典忠 多西他赛冻干粉针及其制备方法
AR063111A1 (es) * 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano

Also Published As

Publication number Publication date
JP2009523770A (ja) 2009-06-25
EP1982699A1 (en) 2008-10-22
GT200800145A (es) 2009-07-21
ZA200805989B (en) 2009-05-27
WO2007082979A1 (es) 2007-07-26
CA2637893A1 (en) 2007-07-26
BRPI0706931A2 (pt) 2011-04-19
EP1994925A4 (en) 2013-01-23
NZ569783A (en) 2011-04-29
UY30100A1 (es) 2008-09-02
AR054215A1 (es) 2007-06-13
EP1994925A1 (en) 2008-11-26
GT200800146A (es) 2008-12-15
ZA200805704B (en) 2009-11-25
JP2009523771A (ja) 2009-06-25
RU2008133761A (ru) 2010-02-27
NZ569968A (en) 2011-07-29
AU2007206877A1 (en) 2007-07-26
CA2638034A1 (en) 2007-07-26
US20090215882A1 (en) 2009-08-27
AU2007206876A1 (en) 2007-07-26
WO2007082978B1 (es) 2007-09-07
MX2008009357A (es) 2008-09-10
RU2429837C2 (ru) 2011-09-27
PE20071243A1 (es) 2008-02-03
BRPI0706932A2 (pt) 2011-04-19
US20090215883A1 (en) 2009-08-27
UY30099A1 (es) 2008-09-02
MX2008009358A (es) 2008-09-10
WO2007082978A1 (es) 2007-07-26

Similar Documents

Publication Publication Date Title
PE20070945A1 (es) Una formulacion farmaceutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubilizante de dicha composicion solida de taxano, y un conjunto de elementos (kit
MX2011011514A (es) Formulaciones de canabidiol y metodos para utilizarlas.
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
AR067824A1 (es) Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer.
GT200500119A (es) Derivados de tetraazabenzo [e] azuleno y sus analogos
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
PE20120777A1 (es) Combinacion de un inhibidor de nucleosido polimerasa con un inhibidor de proteasa macrociclica y su uso en el tratamiento de hepatitis c, fibrosis hepatica y funcion hepatica alterada
CY1115751T1 (el) Φαρμακευτικος συνδυασμος 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλπροπυλ)-φαινολης και ενος αντιεπιληπτικου
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
GT200500235A (es) Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos
AR047928A1 (es) Derivados de tetrahidropiridoindol
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
ECSP10010589A (es) Farmaco contra el cancer de higado
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
CO6400138A2 (es) Compuesto anticancerígeno y composición farmacéutica que lo contiene
EA201290098A1 (ru) Способ получения полимерных композиций на основе проантоцианидина для фармацевтических форм
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CO6231001A2 (es) Estabilizacion de vitamina b12
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto
AR081439A1 (es) Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed